SARS-CoV-2 (2019-nCOV) Detection Antibodies and Antigens
The novel coronavirus SARS-COV-2 has spread into over 100 countries in merely two months. To control this global pandemic, extensive research efforts have been put into the development of rapid diagnostic tools, vaccines, and therapeutic antibodies. To support these studies, Sino Biological has developed a comprehensive panel of antibodies and antigens for this virus. Some of these reagents have already been used to manufacture NMPA-approved COVID-19 diagnostic kits in China.
Sino Biological specializes in recombinant antigen and antibody production. The company’s ProVir collection is the world largest viral antigen bank, including over 800 proteins from 350 viral strains.
SARS-CoV-2 Antigen Detection Kits
The S and N detection kits employ a standard sandwich ELISA, allowing rapid quantification of the N and S antigens.
• All antibodies used in the kits are in-house developed monoclonal antibodies, ensuring batch-to-batch consistency.
• These assays may be used to quantify antigens on the surface of SARS-CoV-2 and/or pseudovirus, as well as antigens expressed recombinantly.
Coronavirus Antigen Array
Sino Biological and Nanommune (Irvine, California) jointly developed the coronavirus antigen array. These arrays are constructed by printing recombinant antigens on a nitrocellulose-coated membrane. It can analyze serum antibodies against 65 antigens from 23 types of viruses known to cause respiratory tract infections, including SARS-COV-2 and the other six coronaviruses. The array is specifically designed for high throughput serological surveillance studies.